TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04989959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PT2385
Description: \[18F\]PT2385 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PT2385
Description: \[18F\]PT2385 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PT2385
Description: \[18F\]PT2385 infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan after \[18F\]PT2385 infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan after \[18F\]PT2385 infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan after \[18F\]PT2385 infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: CT-guided tumor biopsy
Study: NCT05774366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: General anesthesia was induced with 12 mg/kg/hr of intravenous remimazolam. When loss of consciousness was achieved, the infusion rate of remimazolam was reduced to 1mg/kg/hr for maintenance. At the end of surgery, 0.2 mg of flumazenil is administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane (1 minimum alveolar concentration (MAC) of end-tidal desflurane concentration) is used for the maintenance of general anesthesia. Induction of general anesthesia is achieved with 1-2 mg/kg of intravenous propofol bolus.
Study: NCT05437458

Intervention type: OTHER
Intervention: Delirium (exposure)
Description: No interventions.

Intervention type: OTHER
Intervention: Delirium (exposure)
Description: No interventions.

Intervention type: OTHER
Intervention: Delirium (exposure)
Description: No interventions.
Study: NCT05671562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycopene
Description: Capsule containing lycopene 7mg x 2 daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing inactive substance 7mg x 2 daily for 12 weeks
Study: NCT06015867

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention with Wholemeal Bread with Yeast
Description: Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention with Wholemeal Bread with Yeast
Description: Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention with Wholemeal Sourdough Bread
Description: Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention with Wholemeal Sourdough Bread
Description: Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.
Study: NCT05870748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveltamab tazevibulin
Description: Luveltamab tazevibulin is an antibody-drug conjugate targeting FOLR1. It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveltamab tazevibulin
Description: Luveltamab tazevibulin is an antibody-drug conjugate targeting FOLR1. It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim or pegylated G-CSF is approved and used to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs. It increases the proliferation and differentiation of neutrophils.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is a chemotherapy regimen used for treating platinum-resistant ovarian cancer. It inhibits ribonucleotide reductase and DNA polymerase, hindering tumor cell growth and promoting cell death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is a chemotherapy regimen approved for treatment of previously treated ovarian cancer. It stabilizes microtubules, inhibiting tumor cell replication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin is a chemotherapy regimen approved for treating platinum-resistant ovarian cancer. It inhibits DNA and RNA synthesis by intercalating between base pairs, obstructing tumor cell division.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan is a chemotherapy regimen approved for treatment of metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. It binds to topoisomerase I inducing DNA breaks and subsequent tumor cell apoptosis.
Study: NCT05108792

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: observational study, no intervention performed
Study: NCT05782764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
Description: immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
Study: NCT06476197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAT-003
Description: Device: SAT-003(Software) Using SAT-003 for 12 weeks
Study: NCT06359665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 500 mg capsule twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule twice daily
Study: NCT06117280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraxanthine 200 mg
Description: For the three-day test cycle, participants will take one capsule per day amounting to 200mg of paraxanthine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraxanthine 300 mg
Description: For the three-day test cycle, participants will take one capsule per day amounting to 300mg of paraxanthine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will contain resistant dextrin. For the three-day test cycle, participants will take one capsule per day amounting to 300mg of resistant dextrin.
Study: NCT05974748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite 5.25%
Description: The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis 20%
Description: In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
Study: NCT05708612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical Device (SimplyFI)
Description: Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
Study: NCT06580964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Heat pads will be set to a pre-determined, optimized temperature and applied to both legs for 90 min, 7d/wk (6 at-home and 1 in-lab).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Heat therapy
Description: Heat pads will be set to a pre-determined, optimized temperature and applied to both legs for 90 min, 7d/wk (6 at-home and 1 in-lab).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: High-intensity interval training will be performed 3 days per week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: High-intensity interval training will be performed 3 days per week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: High-intensity interval training
Description: High-intensity interval training will be performed 3 days per week for 12 weeks.
Study: NCT05945875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given by IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indium In 111 Panitumumab
Description: Given by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo Single Photon Emission Computed Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Computed Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo standard of care surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo standard of care fluorescence imaging
Study: NCT04808401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
Study: NCT04728347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-021
Description: ARCT-021 single dose
Study: NCT05337306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GogyUp Reader
Description: Participants will have unlimited access to the assistive-reading technologies available in the GogyUp Reader app for help understanding post-visit educational documents on type 2 diabetes mellitus disease management.
Study: NCT06083207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3003
Description: Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
Study: NCT06449638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revita
Description: Participants will receive weekly applications of Revita and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relese
Description: Participants will receive weekly applications of Relese and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cogenex
Description: Participants will receive weekly applications of Cogenex and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enverse
Description: Participants will receive weekly applications of Enverse and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study: NCT05584410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient information
Description: Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient information
Description: Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient information
Description: Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart phone application based exercises
Description: Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web based exercises
Description: Generic osteoarthritis exercise, including about 20 different exercises, provided by real-time videos and written description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group based information
Description: Osteoarthritis specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised rehabilitation
Description: The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
Study: NCT06646185

Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Pads
Description: Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.

Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Pads
Description: Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
Study: NCT05584410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational notifications
Description: Automatic and daily reminders and / or motivational notifications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based rehabilitation
Description: Individualized exercises that the patient performs on their own, i.e. at home or at a gym.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based rehabilitation
Description: Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
Study: NCT06648772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream 0.3%
Description: Roflumilast Cream 0.3%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream
Study: NCT04656535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline placebo comparator for pre-surgery treatment in cohort B4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline placebo comparator for pre-surgery treatment in cohort B4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline placebo comparator for pre-surgery treatment in cohort B4
Study: NCT05978921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength physical exercise programme
Description: 12 multi-joint strength exercises will be developed. Participants will be taught the rating scale of perceived exertion (RPE) based on the number of repetitions in reserve (RIR). Participants will be asked that during the performance of each of the exercises they must perceive an effort between 7-8 within the overall score of the scale (0-10; 0 = no effort at all and 10 = cannot perform one more repetition, i.e. maximal effort). When subjects perform the 12 repetitions with lower perceived exertion than the set effort in two consecutive sessions with full range of motion the training load will be increased by about 2-10% following the American College of Sports Medicine guidelines and reassessed using the RIR-based RPE. Patients in the usual treatment group will continue to participate in their existing rehabilitation programmes, but will not be included in the strength training programme.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal life
Description: Normal life and carry out all the activities they have been doing previously.
Study: NCT05920629

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alcohol consumption
Description: After written consent, patients will enter a run-in period of 2 weeks where they will be asked not to drink any alcohol beverage. Patients with a successful run-in period will be randomized on a 1:1 basis stratified by baseline LVEF (\<50% vs. ≥50%), sex and study site. 110 patients will be assigned to moderate alcohol consumption (1 standard unit a day), and 110 patients to abstinence (no alcohol beverages) for 12 months. We will perform a first echocardiography at randomization and a second at 12 months' follow-up.
Study: NCT04732455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine in Saline
Description: Lidocaine IV infusion (2 mg/kg) in 200 ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: Oral Duloxetine tablet 30 mg once per day starting from the night pre chemotherapy during the whole period of chemotherapy cycle which expected to be three month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
Study: NCT05289362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basket group
Description: Under ERCP, the basket is preferentially used to remove the pancreatic duct stones, and then the balloon is used to evaluate the effect and remove the residual stones.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon group
Description: Under ERCP, the balloon is preferentially used to remove the pancreatic duct stones, and then the basket is used to evaluate the effect and remove the residual stones.
Study: NCT04321538

Intervention type: DEVICE
Intervention: Gocheck Kids
Description: GoCheck Kids is a photoscreening device. It takes a special picture of the eyes that allows for detection of refractive error and eye misalignment.

Intervention type: DEVICE
Intervention: Welch Allyn Spot Vision Screener
Description: The Welch Allyn Spot Vision Screener is a photoscreening device. It takes a special picture of the eyes that allows for the detection of refractive error and eye misalignment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical Exam
Description: Retinoscopy and an oculomotor testing will constitute the physical examination.
Study: NCT05170165

Intervention type: OTHER
Intervention: Using a clinical decision software to provide specific recommendation of a medication at a certain dosage
Description: During routine follow-up, clinicians, cardiologists, and NPs who have a scheduled visit with an enrolled patient will be offered a medication recommendation. The medication recommendation will be generated by the clinical decision support tool. The software will advise the cardiologist whether an HF medication should be initiated, discontinued, or the dosage titrated and if the patient requires labs. In addition, the software, or decision engine (DE), will be run once weekly and every time the patient has new basic metabolic panel results. If the patient is admitted to the hospital, skilled nursing facility, or inpatient rehabilitation unit, the use of DE will be placed on hold until the patient is discharged and at home.
Study: NCT05712590

Intervention type: OTHER
Intervention: dietary habit
Description: As it is observational study, women that follow three different dietary patterns will be inlcuded .

Intervention type: OTHER
Intervention: dietary habit
Description: As it is observational study, women that follow three different dietary patterns will be inlcuded .

Intervention type: OTHER
Intervention: dietary habit
Description: As it is observational study, women that follow three different dietary patterns will be inlcuded .
Study: NCT06135337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thioderm Elate
Description: Test Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Ultra 3
Description: Active Comparator Device